At the same time, the company reports positive interim safety and PK data for the patients recruited into the Ph1b study so far with robust exposure of both methotrexate and the PKenhancer following their subcutaneous administration

NovoBioJect has the potential to significantly improve the global pharmaceutical care of patients with autoimmune dieases. In this novel drug product, the PK enhancer novobiocin is added aiming for a faster onset of disease remission of the treatment in a larger patient population. A successful NovoBioJect not only translates into a decreased disease burden. It also comes with the potential to save billions of euro’s on an annual basis, supporting a more sustainable healthcare system throughtout.

Amplio Pharma CEO Marguerite Mensonides stated:
”We are very pleased to be able to share these two very positive messages simultaneously: the decision by ROM InWest to invest in the company and its technology, and the positive interim data from our Ph1b study in RA patients. NovoBioJect has the potential to not only improve the quality of life for millions of patients, it also offers the opportunity to save billions of euros, contributing directly to a more robust and sustainable healthcare system.”

ROM InWest investment manager Sara Schaafsma stated:
“Amplio Pharma’s vision with NovoBioJect is to improve healthcare without spending billions of euros on yet another expensive biologic drug. Instead, their technology aims to significantly enhance existing medicines with a proven track record, helping to keep overall healthcare costs sustainable. We greatly value our role in supporting this endeavour, which offers clear benefits for society fitting in the space of value-added medicine opportunities where traditional investment funds often lack the mandate to invest.”

Press release on ROM InWest website (in Dutch): https://rominwest.nl/gamechangers/amplio-pharma/